Drugs / PD-L1 CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03330834 | Nov 2017 → Apr 2020 | lung cancer | Sun Yat-sen University | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PD-L1 CAR-T cells | “PD-L1 CAR-T cells are infused on day 0 with 10%, day 3 with 30% and day 7 with 60% , (1-2)×10^6/kg PD-L1 CAR-T cells total.” NCT03330834 ↗ |
| Action | Deplete | “PD-L1 CAR-T cells can effectively kill not only PD-L1 positive tumor cells in vivo but also immunosuppressive cells” NCT03330834 ↗ |
| Modality | Cell therapy | “Chimeric antigen receptor T-Cell (CAR-T) was genetically modified T lymphocytes” NCT03330834 ↗ |